Core Points - Wuhan Heyuan Biotechnology Co., Ltd. has approved the use of raised funds to replace self-raised funds previously invested in fundraising projects and to cover issuance expenses [2][6] - The total amount of raised funds is approximately RMB 2.6 billion, with a net amount of approximately RMB 2.43 billion after deducting issuance expenses [12][2] - The company plans to use RMB 469.56 million to replace self-raised funds for investment projects and RMB 5.19 million for issuance expenses [4][5] Fundraising Overview - The company issued 89,451,354 shares at a price of RMB 29.06 per share, raising a total of RMB 2,599,456,347.24 [12][2] - After deducting issuance expenses of RMB 169,031,770.68, the net amount raised is RMB 2,430,424,576.56 [12][2] - All raised funds are managed in a special account, with a tripartite supervision agreement in place [3] Investment Project Details - The company has pre-invested RMB 469,556,343.17 in fundraising projects using self-raised funds [4] - The issuance expenses totaled RMB 169,031,770.68, with RMB 5,187,028.30 already paid from self-raised funds [5] Approval Process - The board of directors approved the use of raised funds for replacement at a meeting held on November 21, 2025 [6] - The replacement of funds is compliant with relevant regulations and does not require shareholder approval [6][7] Cash Management Plan - The company plans to manage temporarily idle raised funds (including oversubscription funds) to enhance fund utilization efficiency [9][10] - The cash management will involve purchasing safe, liquid, principal-protected products, with a limit of RMB 2.1 billion [13][10] - The cash management period is valid for 12 months from the board's approval date [13][14] Risk Management - The company will select reputable financial institutions for cash management products and will monitor investment risks closely [19][20] - Independent directors and the audit committee will oversee the use of funds [20][21] Impact on Company Operations - The cash management initiative is designed to improve fund efficiency without affecting ongoing investment projects [23] - The company aims to generate additional returns for itself and its shareholders through this cash management strategy [23][25]
武汉禾元生物科技股份有限公司 关于使用募集资金置换预先投入募投项目及已支付发行费用的自筹资金的公告